Dynavax Technologies Corp. (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Group in a note issued to investors on Friday, American Banking and Market News reports. They currently have a $3.00 target price on the stock. Jefferies Group’s target price suggests a potential upside of 169.06% from the company’s current price.
The analysts wrote, “DVAX had recently provided an update on its Heplisav safety study, HBV-23, the critical trial necessary to address the FDA’s complete response letter, and so there was no new update in this earnings release. Financials for the quarter were in line. We continue to expect the HBV-23 trial to support a favorable safety and risk-benefit profile for Heplisav, with data around the end of 2015. We maintain our $3 price target and Buy rating.”
Dynavax Technologies Corp. (NASDAQ:DVAX) traded up 2.24% during mid-day trading on Friday, hitting $1.14. 1,194,957 shares of the company’s stock traded hands. Dynavax Technologies Corp. has a 1-year low of $0.98 and a 1-year high of $5.00. The stock’s 50-day moving average is $1.21 and its 200-day moving average is $1.52. The company’s market cap is $208.6 million.
Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $1.83 million. Analysts expect that Dynavax Technologies Corp. will post $-0.38 EPS for the current fiscal year.
In other Dynavax Technologies Corp. news, Director Peggy V. Phillips bought 93,023 shares of Dynavax Technologies Corp. stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $1.08 per share, with a total value of $100,464.84. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.